胡HML
Lv1
90 积分
2024-01-02 加入
-
A multicenter, randomized, double-blinded, placebo-controlled, phase Ⅲ study evaluating the efficacy and safety of Xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis
4天前
已完结
-
Efficacy of a second IL-17 inhibitor in patients with psoriasis: a systematic review and meta-analysis - Supplementary
13天前
已完结
-
Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis
1个月前
已完结
-
A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis
1个月前
已完结
-
CUTANEOUS MANIFESTATIONS OF DIABETES MELLITUS
2个月前
已完结
-
A multicenter, randomized, double-blinded, placebo-controlled, phase Ⅲ study evaluating the efficacy and safety of Xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis
2个月前
已完结
-
A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis
2个月前
已完结
-
43840 Guselkumab in patients with scalp psoriasis: A post hoc analysis of the VOYAGE 2 trial
3个月前
已完结
-
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study
3个月前
已完结
-
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
3个月前
已完结